Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Luteolin and diosmin/diosmetin as novel stat3 inhibitors for treating autism

a technology of stat3 inhibitors and diosmin, which is applied in the direction of biocide, drug composition, metabolic disorder, etc., can solve the problems of increased risk of fetal neurological injury, repetitive behavior and unusual attachment of children with autism, and increased risk of autism-related neurological injury, etc., to reduce inflammation

Inactive Publication Date: 2011-08-18
UNIV OF SOUTH FLORIDA
View PDF9 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Children with autism have difficulties in social interaction and communication and may show repetitive behaviors and have unusual attachments to objects or routines.
Maternal infection increases the risk of fetal neurological injury.
In support, Samuelsson et al., 2006 intraperitoneally injected IL-6 in pregnant rats for 3 days resulting in severe effects on the offspring.
Therefore, prolonged exposure to elevated IL-6 in utero causes a deficit in working memory (for reviews see Patterson 2008).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Luteolin and diosmin/diosmetin as novel stat3 inhibitors for treating autism
  • Luteolin and diosmin/diosmetin as novel stat3 inhibitors for treating autism
  • Luteolin and diosmin/diosmetin as novel stat3 inhibitors for treating autism

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0047]In the following detailed description of the preferred embodiments, reference is made to the accompanying drawings, which form a part hereof, and within which are shown by way of illustration specific embodiments by which the invention may be practiced. It is to be understood that other embodiments may be utilized and structural changes may be made without departing from the scope of the invention.

[0048]Throughout this application various publications are referenced. Disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.

[0049]The “therapeutically effective amount” for purposes herein is thus determined by such considerations as are known in the art. A therapeutically effective amount of the flavonoids such as luteolin, diosmin, or diosmetin, their analogues or any combination thereof is that amount necessary to provide a therapeutical...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationsaaaaaaaaaa
pHaaaaaaaaaa
exploration timeaaaaaaaaaa
Login to View More

Abstract

The present invention includes methods for the treatment of autoimmune disorders such as autism, schizophrenia, and type 1 diabetes. Flavonoids, luteolin, diosmin, and diosmin's aglycone form, diosmetin, were found to inhibit activation / phosphorylation of STAT3 induced by IL-6 in cultured neuronal cells. Furthermore, mice treated with diosmin showed a significant reduction of autistic phenotype induced by IL-6 through inhibition of STAT3 activation.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of prior filed International Application, Serial Number PCT / US2009 / 062753, entitled, “Luteolin and Diosmin / Diosmetin as Novel STAT3 Inhibitors for Treating Autism” filed Oct. 30, 2009, which claims priority to U.S. Provisional Patent Application Ser. No. 61 / 109,538 entitled, “Luteolin and Diosmin / Diosmetin as Novel STAT3 (Signal Transducer and Activator of Transcription) Inhibitors for Treating Autism”, filed Oct. 30, 2008, which are herein incorporated by reference.FIELD OF INVENTION[0002]The present invention relates to compositions and methods for the screening and treatment of autoimmune disorders such as autism, schizophrenia, and type 1 diabetes. Specifically this invention uses flavonoids to inhibit the activation / phosphorylation of STAT3 induced by IL-6.BACKGROUND OF THE INVENTION[0003]Autism is a brain disorder that begins in early childhood and persists throughout adulthood. It affects three cr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/7048A61K31/353A61P3/10A61P25/18A61P25/28
CPCA61K31/352A61K31/7048A61K31/353A61K2300/00A61P25/00A61P25/18A61P25/28A61P3/10
Inventor TAN, JUNLUO, DEYAN
Owner UNIV OF SOUTH FLORIDA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com